Johnson & Johnson’s (J&J’s) Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to ...

Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...

Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European ...

Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA study.

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.

Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved an extension of marketing ...

"The survival curve tells a clear story. RYBREVANT plus LAZCLUZE helps patients live longer, and the benefit keeps growing over time," said trial investigator Professor Nicolas Girard*, M.D., Ph.D ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line EGFR-mutated NSCLC over osimertinib.

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso on overall survival. But analysts say the next step is getting a ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell ...